Avalyn Pharma (AVLN) Stock Forecast & Price Target
Score
Avalyn Pharma Inc. Common Stock price target
| AVLN | |
|---|---|
| Low | $51.00 |
| Average | $60.00 |
| High | $80.00 |
| Upside vs current price | +98.2% |
The average target of $60.00 is +98.2% versus the current AVLN price of $30.28.
Avalyn Pharma Inc. Common Stock analyst ratings
| Rating | Analysts |
|---|---|
| Strong buy | 0 |
| Buy | 1 |
| Hold | 0 |
| Sell | 0 |
| Strong sell | 0 |
| Consensus | Buy |
1 analyst covers AVLN.
Is Avalyn Pharma Inc. Common Stock a buy or sell?
Of the 1 analyst covering Avalyn Pharma Inc. Common Stock, 1 rates it a buy (0 strong buy and 1 buy), 0 rate it a hold, and 0 rate it a sell (0 sell and 0 strong sell).
The AVLN consensus label is Buy, beside 1 buy-side ratings and 0 sell-side ratings.
The average target of $60.00 implies +98.2% versus the current price of $30.28.
The AVLN rating block is 1 published views with a Buy label. It does not tell you whether to buy or sell.
Reading the Avalyn Pharma Inc. Common Stock forecast
A wide spread is the story on AVLN. Targets run from $51.00 to $80.00, with $60.00 as the average.
The gap from the $30.28 price to the AVLN average is +98.2%.
The AVLN rating mix is lopsided rather than split: 1 of 1 analyst is on the buy side, 0 are at hold, and 0 are on the sell side, and the published consensus is Buy.
With 1 analyst on AVLN, the average is a small sample.
Avalyn Pharma Inc. Common Stock forecast questions
What is the AVLN price target?
The published range for AVLN is $51.00 to $80.00, with an average of $60.00. That average is +98.2% versus the current price of $30.28.
Is Avalyn Pharma Inc. Common Stock a buy or sell?
Of the 1 analyst covering Avalyn Pharma Inc. Common Stock, 1 rates it a buy, 0 rate it a hold, and 0 rate it a sell. The consensus is Buy, leaving AVLN at 1 buy ratings, 0 holds, and 0 sells.
What is the EPS estimate for Avalyn Pharma Inc. Common Stock?
No EPS estimate for the next two fiscal years is on file for Avalyn Pharma Inc. Common Stock.
What is the revenue estimate for Avalyn Pharma Inc. Common Stock?
No revenue estimate for the next two fiscal years is on file for Avalyn Pharma Inc. Common Stock.
How many analysts cover AVLN?
1 analyst covers AVLN. Their consensus on AVLN is Buy, across those 1.